Dr. Reddy's Q2 Profit Falls 36% on Lower North America Lenalidomide Sales; RDY Gains Pre-Market

Dr. Reddy's Laboratories Ltd. (RDY) reported a 36% decline in second-quarter fiscal 2027 profit, as revenue slipped on weaker lenalidomide sales in North America. Profit fell to INR 9,134 million, or INR 11.10 per share, from INR 14,268 million, or INR 17.25 per share, a year earlier. Profit before income tax dropped to INR 12,277 million from INR 18,350 million, the company announced Friday. Revenue declined to INR 86,708 million from INR 88,051 million, primarily due to lower North America lenalidomide revenues. Shares of the Hyderabad-based generics maker were trading at $13.32 pre-market, up 0.76% on the NYSE.